Rhodiola rosea and endurance: positive averages meet product uncertainty
A guide to Rhodiola endurance evidence, extract standardization, trial quality, biomarkers, safety and athlete use.

Recent pooled research reports modest endurance effects, but heterogeneous protocols, risk of bias and extract differences limit product-wide conclusions.
The latest meta-analysis is encouraging but heterogeneous
A 2025 systematic review and meta-analysis combined 26 randomized trials involving 668 healthy participants. Pooled results favored Rhodiola rosea for maximal oxygen uptake, time to exhaustion and time-trial performance, along with several oxidative-stress and muscle-damage markers. Inflammatory markers did not improve. The authors also reported meaningful heterogeneity across studies. A positive pooled average is therefore a reason for interest, not proof that every formula or athlete will benefit. The size and consistency of the performance effect matter more than the simple presence of statistical significance.

Earlier quality concerns remain relevant
A 2023 systematic review of 13 randomized trials found heterogeneous results and identified unclear or high risk of bias in most included studies. It suggested possible acute endurance and perceived-exertion benefits but called for higher-quality trials. A newer meta-analysis can add participants and precision without automatically correcting limitations in the underlying experiments. Readers should examine randomization, blinding, preregistration, attrition and whether the primary endpoint was defined before accepting a confident product claim.
Rhodiola is not one standardized intervention
Products vary in species verification, root material, extraction process and declared rosavin or salidroside content. A study of one characterized extract does not validate a different powder or multi-herb blend. The front label may emphasize a milligram amount while the chemical profile remains unclear. Consumers should compare the exact extract, standardization, serving and duration with the cited research. If a seller cites only general Rhodiola literature, it should not imply that its own bottle has been clinically tested.
Biomarkers should not replace performance
Lower creatine kinase, lactate or malondialdehyde can support a mechanistic discussion, but they do not automatically mean an athlete ran faster or recovered for the next session. The 2025 analysis reported changes in both performance and biomarkers, yet each outcome should be described separately. Time to exhaustion can also produce larger effects than a fixed-distance time trial and may be less representative of competition. A fair summary names the test rather than collapsing every favorable measure into better endurance.

Herbal safety and sport quality deserve scrutiny
Rhodiola can cause adverse effects and may interact with medicines; long-term sport-specific safety data are limited. People managing mood disorders, blood pressure, pregnancy or complex medication regimens should discuss use with a clinician. Competitive athletes also need independent certification because botanical identity and purity cannot be confirmed from a research paper. Multi-ingredient adaptogen products make attribution especially difficult and can add stimulants or other herbs with their own risks.
Use the evidence without overpromising
An athlete considering Rhodiola can identify the exact goal, select a comparable trial, check the extract match and test tolerability away from competition. The recent pooled evidence is more favorable than for many herbal ergogenic aids, but it does not establish one optimal product, dose or schedule. Training, carbohydrate availability, sleep and pacing remain much better established. The measured conclusion is that Rhodiola may modestly improve selected endurance outcomes on average, while formulation uncertainty and study quality prevent a blanket recommendation across all athletes and products.
Separate acute and chronic use
A single pre-exercise dose asks whether Rhodiola changes one session, while several weeks of supplementation asks about adaptation, recovery or accumulated effects. Pooling both designs may produce an average that does not translate into one practical schedule. The 2023 review suggested different patterns for acute and chronic studies, reinforcing the need to name the protocol. Consumers should not assume that a formula tested once has proven long-term value or that a chronic trial establishes a same-day boost. Duration also changes the safety and cost question. Testing an herbal product away from competition can reveal immediate tolerability, but absence of short-term symptoms does not settle long-term safety. The claim, study duration and planned use should match.
Reporting adverse events and adherence consistently would also help determine whether a statistically favorable protocol is practical across a full training block.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.